Itamar Medical Ltd., a pioneering name in the medical technology sector, is headquartered in Israel (IL) and operates extensively across global markets. Founded in 1997, the company has established itself as a leader in the development of innovative solutions for sleep and cardiovascular disorders. Itamar Medical is renowned for its flagship product, WatchPAT, a unique home sleep apnea testing device that combines advanced technology with user-friendly design, setting it apart in the industry. The company’s commitment to enhancing patient care and improving diagnostic accuracy has earned it a prominent position in the healthcare landscape. With a focus on non-invasive monitoring solutions, Itamar Medical continues to achieve significant milestones, contributing to advancements in sleep medicine and cardiovascular health.
How does Itamar Medical Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Itamar Medical Ltd.'s score of 63 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Itamar Medical Ltd., headquartered in Israel (IL), currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Asahi Kasei Corporation, which may influence its climate commitments and reporting practices. Asahi Kasei Corporation, the parent company, has established various climate initiatives, but specific reduction targets or achievements for Itamar Medical Ltd. have not been disclosed. The absence of documented reduction targets or climate pledges indicates that Itamar Medical Ltd. may still be in the early stages of formalising its sustainability strategy. Given the lack of direct emissions data and specific commitments from Itamar Medical Ltd., it is essential to monitor future disclosures for any developments in their carbon emissions reporting and climate action initiatives.
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000,000 | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | - | 0,000,000,000 | - | - | - | - | - | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
Itamar Medical Ltd.'s Scope 3 emissions, which decreased by 0% last year and increased by approximately 113% since 2015, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 79% of total emissions under the GHG Protocol, with "End-of-Life Treatment of Sold Products" being the largest emissions source at 41% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Itamar Medical Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.